30 filings · most recent first
CDTX 8-K Filings
Cidara Therapeutics Merger With Merck Sharp Dohme Llc Complete
Cidara Therapeutics Reports Q3 2025 Financial Results And Corporate Update
Cidara Therapeutics Signs Agreement With Barda For Cd388 Development
Cidara Therapeutics Reports Second Quarter 2025 Financial Results And Corporate
Cidara Therapeutics Announces Positive Topline Results For Cd388 In Phase 2B
Cidara Therapeutics Increases Authorized Share Count
Cidara Therapeutics Reports First Quarter 2025 Financial Results And Provides
Cidara Therapeutics Reports Full Year 2024 Financial Results And Business
Board Changes At Cidara Therapeutics
Cidara Therapeutics Announces 105 Million Private Placement
Cidara Therapeutics Reports Third Quarter 2024 Financial Results And Corporate
Cidara Therapeutics Initiates Phase 2B Navigate Trial For Cd388 Influenza
Cidara Therapeutics Announces Workforce Reduction And Clinical Trial Plans
Cidara Therapeutics Reports Second Quarter 2024 Financial Results And Corporate
Cidara Therapeutics Inc Announces Approval Of 2024 Equity Incentive Plan And
Cidara Therapeutics Announces 2023 Executive Bonus Determinations
Cidara Therapeutics Reports Q1 2024 Financial Results And Key Corporate Updates
Cidara Therapeutics Updates Investor Presentation
Cidara Therapeutics Sells Rezafungin Acetate Assets To Napp
Cidara Therapeutics Announces Licensing Agreement With Janssen And Private
Cidara Therapeutics Announces Sale Of Rezafungin Acetate Assets To Napp
Cidara Therapeutics Announces Reverse Stock Split And Reports Q4 2023 Financial
Cidara Therapeutics Announces Restatement Of Prior Financial Statements Due To
Cidara Therapeutics Inc Approves Reverse Stock Split
Nasdaq Grants Listing Continuation To Cidara Therapeutics
Merck To Acquire Cidara Therapeutics For 92 Billion
Cidara Therapeutics Expands Phase 3 Trial For Cd388 Based On Fda Feedback
Cidara Therapeutics Announces Underwritten Public Offering Of Common Stock
Cidara Therapeutics Terminates Atm Prospectus
Cidara Therapeutics Announces Cfo Transition